Adimora IJ et al. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. N Cancer 2022;128(16):3019-26. Abstract

Cai T et al. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun 2022;13(1):2228. Abstract

Cuglievan B et al. Blastic plasmacytoid dendritic cell neoplasm: A comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 2022;37(9):1767-78. Abstract

Gangat N et al. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol 2022;97(2):E62-7. Abstract

Griffin GK et al. Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature 2023;618(7966):834-41. Abstract

Khoury J et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia 2022;36(7):1703-19. Abstract

Pemmaraju N et al. Interim analysis of a registration-enabling study of pivekimab sunirine (PVEK, IMGN632) a CD123-targeting antibody-drug conjugate, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). EHA 2023;Abstract S139.

Pemmaraju N et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol 2022;40(26):3032-6. Abstract

Pemmaraju N et al. Risk-adjusted safety analysis of pacritinib in patients with myelofibrosis. EHA 2022;Abstract P1068.

Pemmaraju N et al. North American blastic plasmacytoid dendritic cell neoplasm consortium: Position on standards of care and areas of need. Blood 2023;141(6):567-78. Abstract

Togami K et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis. Cancer Discov 2022;12(2):522-41. Abstract